# VERITAC-2 (NCT05654623)

> A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05654623
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Advanced Breast Cancer
- Interventions: ARV-471; Fulvestrant
- Enrollment: 624
- Primary outcome: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants
- Primary outcome: PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation

## Commentary we found

- X threads: 64
- YouTube: 55
- Podcasts: 29
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=veritac-2-nct05654623

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05654623", "email": "<work email>"}; the inbox owner confirms by the emailed link.